Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UDR5
UPID:
AASS_HUMAN
Alternative names:
LKR/SDH
Alternative UPACC:
Q9UDR5; O95462
Background:
Alpha-aminoadipic semialdehyde synthase, mitochondrial, also known as LKR/SDH, plays a pivotal role in lysine degradation. This bifunctional enzyme catalyzes the initial steps, crucial for maintaining amino acid balance and energy production within cells.
Therapeutic significance:
The enzyme's malfunction is linked to Hyperlysinemia, 1, and 2,4-dienoyl-CoA reductase deficiency, diseases characterized by metabolic and neurological disturbances. Targeting the enzyme's pathways offers a promising avenue for therapeutic intervention in these conditions.